Roorkee’s IIT has just rolled out a cutting-edge antibody discovery platform that’s set to transform how we tackle some of the world’s toughest diseases. Targeting cancer, infectious outbreaks, autoimmune conditions, and novel pathogens, this next-gen system identifies ultra-stable, high-affinity antibodies at record speeds.
What makes it stand out? A massive library of single-domain antibodies—nanobodies—that boast exceptional diversity and robustness. These tiny powerhouses bind tightly to their targets, delivering pinpoint accuracy in diagnostics and therapies.
In an era where rapid response can mean the difference between containment and crisis, this platform slashes discovery times dramatically. It’s a boon for emergency healthcare scenarios, ensuring quicker deployment of life-saving tools.
‘We’re building India’s capacity to fight diseases head-on with affordable, homegrown solutions,’ said Prof. Rajesh Kumar, lead researcher from the Biosciences and Bioengineering Department.
Echoing national visions like Atmanirbhar Bharat, the initiative cuts dependency on foreign biologics, spurs IP creation, and accelerates lab-to-clinic translations. It’s particularly crucial for resource-constrained regions grappling with healthcare access.
Prof. K.K. Pant, IIT Roorkee’s Director, praised the synergy: ‘Fundamental science paired with industry partnerships is key to addressing real-world health hurdles.’
To amplify impact, IIT Roorkee inked an MoU with Imgenex India, focusing on joint R&D in antibody tech, diagnostics, therapeutics, and bioprocessing. This collaboration promises to scale innovations for broader societal benefit.
As India pushes for biotech self-sufficiency, this platform emerges as a cornerstone, equipping the country to handle current and future health challenges with resilience and ingenuity.
